Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Heribanova, Lucie
SWIFT-2, NCT04718103 / 2020-003611-10: A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype Jul 2024 - Dec 2024 : H2'24 - Acceptance of regulatory submission in US (based on SWIFT-1 trial) for asthma	Completed	3	397	Europe, Canada, Japan, US, RoW	GSK3511294, Depemokimab, Placebo	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	04/24	04/24
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)	Recruiting	3	160	Europe, Canada, Japan, US, RoW	Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab	GlaxoSmithKline	Eosinophilic Granulomatosis With Polyangiitis	10/25	11/25
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial	Recruiting	3	120	Europe, Canada, Japan, US, RoW	Depemokimab, Placebo	GlaxoSmithKline	Hypereosinophilic Syndrome	02/26	03/26